The Study of CM326 in Adult Subjects With Atopic Dermatitis

This is a open-label, multi-center study to evaluate the safety and efficacy of CM326 in atopic adrmatitis subjects.

Inclusion Criteria:With confirmed Atopic Dermatitis (AD) at the screening.Have the ability to understand the nature of the study and voluntarily sign the informed consent.Be able to communicate well with investigators and follow up protocol requirements.The subjects agreed to use highly effective contraceptive measures during the study.Exclusion Criteria:Not enough washing-out period for previous therapy.Received allergen specific immunotherapy (desensitization) within 6 months prior to baseline.Major surgery is planned during the study period.Women who are pregnant or breastfeeding, or who plan to become pregnant during the study.